摘要
目的对多西紫杉醇联合替吉奥治疗蒽环类耐药晚期乳腺癌的临床治疗效果和不良反应情况进行分析与探讨。方法随机选取该院于201 1年1月—2014年3月收治的130例蒽环类耐药晚期乳腺癌的患者进行实验组和对照组的分组,给予实验组患者多西紫杉醇和替吉奥的联合治疗,给予对照组患者紫杉醇和顺铂的联合治疗。对两组患者的治疗效果和不良反应情况进行对比分析。结果经过治疗后,实验组的治疗有效率为96.9%,对照组的治疗有效率为84.6%,且实验组出现的不良反应情况要明显少于对照组,差异有统计学意义(P<0.05)。结论 多西紫杉醇联合替吉奥治疗蒽环类耐药晚期乳腺癌可以取得确切的疗效,患者的不良反应较少,因此值得在临床中推广和应用。
Objective Analysis and observation of clinical therapeutic effect and adverse reaction of combination of docetaxel and S-1 in treatment of anthracycline resistant advanced breast cancer. Methods Group 130 cases of anthracene were randomly select-ed in our hospital in 2011 January to 2014 March were ring resistant advanced breast cancer patients were the experimental group and the control group,Combination therapy administered to the experimental group patients with docetaxel and s-1,Patients in the treatment group were given control combined with paclitaxel and cisplatin. Comparative analysis of two groups of patients the treat-ment effect and adverse reaction. Results After treatment,The effective rate of the treatment of the experimental group is 96.9%, The effective rate of the treatment group is 84.6%,Adverse reactions and the experimental group appeared to be significantly less than the control group,P〈0.05, with significant difference. Conclusion Combination of docetaxel and S-1 in treatment of anthracy-cline resistant advanced breast cancer can obtain the exact effect,The adverse reaction of patients with less,It is worthy of clinical popularization and application.
出处
《中外医疗》
2015年第8期133-134,共2页
China & Foreign Medical Treatment
